alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › acetylcholinesterase

acetylcholinesterase

234 studies tagged acetylcholinesterase, dated 1977-11-01 to 2026-10-25. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Integrated Transcriptomic and Structural Prioritization of Sulforaphane Targets in Neurodegeneration: A Multi-Dataset In Silico Study 2026-10-25
  2. Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling 2026-10-20
  3. DNA-Encoded Library-Guided Discovery of a First-in-Class Molecular Glue of the NOS1AP-SCRIB Complex in Alzheimer’s Disease Patient-Derived Neurons 2026-10-18

Studies

234 studies carry this tag.

Date range

1977 to 2026

Top journals

  • Research Square 9
  • Journal of medicinal chemistry 7
  • International journal of molecular sciences 6
  • Journal of Alzheimer's disease : JAD 6
  • Nature reviews. Drug discovery 6

154 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Neurosteroid metabolism in the human brain

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. European Journal of Endocrinology 2001-12-01 Risk factors

    This review summarizes the current knowledge of the biosynthesis of neurosteroids in the human brain, the enzymes mediating these reactions, their localization and the putative effects of neurosteroids.

  2. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biological psychiatry 2001-02-01 Treatments

    Cholinesterase inhibitors are the only approved drug treatment for patients with mild to moderately severe Alzheimer's disease.

  3. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current medical research and opinion 2001-01-01 Treatments

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the elderly, characterised by widespread loss of central cholinergic function.

  4. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Experimental neurology 2000-06-01 End-of-life care

    Life's Journey If life is indeed a journey, then poetry must be the map that reveals all its topographic possibilitiesellipsis while science is the compass that keeps us from getting lost. -R. T. Bartus, Simple Words for Complex Lives, (c) 1998 In the nearly 20 years since the cholinergic hypothesis was initially formulated, significant progress has been achieved.

  5. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current medicinal chemistry 2000-03-01 Treatments

    A wide range of evidence shows that acetylcholinesterase (AChE) inhibitors can interfere with the progression of Alzheimer's disease (AD).

  6. beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Journal of biological chemistry 2000-02-01 Risk genes beyond APOE

    Alzheimer's disease pathology is characterized by the presence of neuritic plaques and the loss of cholinergic neurons in the brain.

  7. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Annals of neurology 2000-02-01 Treatments

    Human immunodeficiency virus type 1 (HIV-1) proteins Tat and gp120 have been implicated in the pathogenesis of dementia associated with HIV infection.

  8. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Pharmacotherapy 2000-01 Treatments

    Rivastigmine is a cholinesterase inhibitor (ChEI) with a structural formula different from that of currently available ChEIs.

  9. Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Pathology international 1999-11-01 Risk factors

    The genomic structure of ChAT is unique compared with other enzymes for neurotransmitters.

  10. Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Expert opinion on investigational drugs 1999-10 Treatments

    Alzheimer's disease is, in part, characterised by the loss of neurones in the basal forebrain cholinergic cells that project to the cerebral cortex and hippocampus.

  11. The cholinergic hypothesis of Alzheimer's disease: a review of progress

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neurology, neurosurgery, and psychiatry 1999-02-01 Treatments

    Alzheimer's disease is one of the most common causes of mental deterioration in elderly people, accounting for around 50%-60% of the overall cases of dementia among persons over 65 years of age.

  12. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Drug safety 1998-12-01 Treatments

    Tacrine is associated with hepatotoxicity while other cholinesterase inhibitors seem devoid this adverse effect.

  13. Glutamate in CNS disorders as a target for drug development: an update

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Drug news & perspectives 1998-11-01 Risk factors

    The authors provide an extensive review of new data related to the role of glutamate in CNS disorders, describing new aspects in glutamate and glutamatergic receptors-NMDA receptors, NR2B-selective antagonists, non-NMDA ionotropic glutamate receptors, N-acetylaspartylglutamate, and glutamate and glycine transporters.

  14. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Clinical therapeutics 1998-07-01 Treatments

    Rivastigmine (ENA 713, or carbamoylatine) is an acetylcholinesterase (AChE) inhibitor with brain-region selectivity and a long duration of action.

  15. Human neuronal nicotinic receptors

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Progress in neurobiology 1997-10-01 Clinical safety

    Nicotine is a very widely used drug of abuse, which exerts a number of neurovegetative, behavioural and psychological effects by interacting with neuronal nicotinic acetylcholine receptors (NAChRs).

  16. Central cholinergic systems and cognition

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Annual review of psychology 1997-01-01 Risk factors

    The organization and possible functions of basal forebrain and pontine cholinergic systems are reviewed.

  17. Adenosine A2 receptor-mediated excitatory actions on the nervous system

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Progress in neurobiology 1996-02-01 Brain scans and imaging

    The distribution, molecular structure and role of adenosine A2 receptors in the nervous system, is reviewed.

  18. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Proceedings of the National Academy of Sciences 1996-01-09 Disease mechanisms

    Neurodegenerative diseases, in which neuronal cell disintegrate, bring about deteriorations in cognitive functions as is evidenced in millions of Alzheimer patients.

  19. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Brain research 1996-01-01 Treatments

    Substantial evidences suggest that the increased cerebral deposition, and neurotoxic action of the beta-amyloid peptide, the major constituent of senile plaques, may represent the underlying cause of the cognitive deficits observed in Alzheimer's disease.

  20. Pharmacology of nicotine: addiction and therapeutics

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Annual review of pharmacology and toxicology 1996-01-01 Risk factors

    Nicotine maintains tobacco addiction and has therapeutic utility to aid smoking cessation and possibly to treat other medical diseases.

  21. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neuropharmacology 1995-10-01 Treatments

    The data from the present study do not lend support to the idea that low affinity, open channel NMDA receptor blockers are also effective in models of epilepsy at doses having little effect on physiological processes.

  22. Anticholinesterases: medical applications of neurochemical principles

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neurochemistry 1995-05-01 Risk factors

    Cholinesterases form a family of serine esterases that arise in animals from at least two distinct genes.

  23. Alzheimer disease, attention, and the cholinergic system

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer disease and associated disorders 1995-01-01 Cognitive tests and assessment

    Recent neuropsychological studies suggest that, in addition to prominent mnemonic dysfunction, attentional impairments are a core feature of Alzheimer disease (AD).

  24. A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 68 out of 100. The American journal of psychiatry 1994-01 Clinical trials

    In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth factor.

  25. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. PubMed 1994-01-01 Treatments

    The pharmacological inhibition of excitatory amino acid neurotransmission has evolved to be a major topic in neuropharmacology since enhanced synaptic action of glutamate and possibly other related neurotransmitters has been suggested to play a role both in acute neurological conditions such as ischemia and epilepsy and in chronic degenerative neurological diseases including Parkinson's disease, Huntington's disease and Alzheimer's disease.

  26. No response to high-dose muscarinic agonist therapy in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurology 1988-04 Clinical trials

    Cholinergic deficiency is the most consistent transmitter system abnormality in Alzheimer's disease.

  27. NON-CHOLINERGIC NEUROTRANSMITTER ABNORMALITIES IN ALZHEIMER'S DISEASE

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. British Medical Bulletin 1986-01-01 Disease mechanisms

    Apart from the damago to ascending cholinergic projections in Alzheimer's disease, biochemical studies on human brain post mortem have revealed a number of other neurochemical abnormalities.

  28. Neuropeptides in Alzheimer type dementia

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of the neurological sciences 1983-12-01 Disease mechanisms

    Five neuropeptides (cholecystokinin (CCK), vasoactive intestinal polypeptide (VIP), somatostatin (SRIF), neurotensin (NT) and substance P (SP)) were measured in 14 brain areas (4 cortical areas, hippocampus, amygdala, 3 striatal areas, 2 thalamic areas and 3 subcortical areas-- septum, substantia innominata and hypothalamus) in 12 brains with neuropathologically confirmed Alzheimer type change and in 13 control brains.

  29. Biochemical Assessment of Serotonergic and Cholinergic Dysfunction and Cerebral Atrophy in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Neurochemistry 1983-01-01 Disease mechanisms

    Markers of serotonin synapses in entire temporal lobe and frontal and temporal neocortex were examined for changes in Alzheimer's disease by use of both neurosurgical and autopsy samples.

  30. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Nature 1980-11-01 Brain tissue and pathology

    Both Alzheimer's disease and senile dementia of the Alzheimer type (AD/SDAT) are progressive dementias characterized neuropathologically by the presence in the cerebral cortex of numerous neurofibrillary tangles and neuritic plaques.

  31. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Brain research 1979-08-01 Tau biomarkers

    Choline acetyltransferase (ChAT), acetylcholinesterase (AChE) and glutamic acid decarboxylase (GAD) activities were measured in 20 brain regions from autopsied control and senile dementia of the Alzheimer type (SDAT) cases.

  32. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. British medical journal 1978-11-01 Risk factors

    Necropsy brain tissue from normal (control) patients and patients with depression and dementia was examined for activities of various cholinergic components, and these related to the degree of senile plaque formation and extent of intellectual impairment.

  33. CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neuropathology and Applied Neurobiology 1978-07-01 Risk factors

    Acetyl- and butyryl-cholinesterase activities have been measured biochemically in normal brain tissue, in senile dementia of Alzheimer type and in mental disorders without Alzheimer-type abnormalities.

  34. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of the neurological sciences 1977-11-01 Risk factors

    Reductions in 2 neurotransmitter synthesizing enzymes in brain, glutamic acid decarboxylase (GAD) and choline acetyltransferase (CAT), have been found in dementias of different origins, including senile dementia (Alzheimer type).

From across this tag

7 of the 234 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 7. The same 7 appear here every time.

All topic tags with their study counts